A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth. Medscape Medical News
Category: News
US FDA Declines to Approve Aldeyra’s Eye Disease Drug
The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, the company said on Thursday, sending its shares… Reuters Health Information
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt…
Sponsor Pulls Plug on Trials of Add-On AMD Treatment
An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 trials, so the sponsor halted both trials. Medscape Medical News
Gene Therapy: Medical Progress Has a Price, Says Ethicist
Ethicist Art Caplan discusses progress in gene therapy research and the need for medical professionals and regulators to tolerate appropriate risk. Medscape Business of Medicine
Nexus Pharmaceuticals Launches Fluorescein 2 mL
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhanc…
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April
LONDON & SEATTLE–(BUSINESS WIRE)– #ophthalmology–Tenpoint Therapeutics Ltd. to Participate in the RBC Capital Markets Virtual Ophthalmology and 24th Annual Needham Virtual Healthcare Conferences
HLA-B27 Status Linked to Poor Outcomes in JIA After 18 Years
HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after disease onset, with the odds being higher in men than in women. Medscape News UK
EMA Recommends Ryjunea for Pediatric Myopia
The atropine-based eye drop is designed to slow myopia progression in children. Medscape Medical News
Semaglutide Use Linked to Risk for Vision Loss in Diabetes
Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds. Medscape Medical News
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to…
The Ethical Consequences of the New Administration
Ethicist Art Caplan discusses the ethical consequences of the new administration. Medscape Business of Medicine
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista pla…
Cataract Surgery May Help Prevent Falls and Fractures
Cataract extraction with intraocular lens insertion is associated with reduced odds of falls and major injuries in older adults with age-related cataracts, a new study finds. Medscape Medical News
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA–(BUSINESS WIRE)–Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA–(BUSINESS WIRE)–Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bau…
Multiple Drug Classes Can Up Risk for Floppy Iris Syndrome
Researchers find new drug associations with floppy iris syndrome, including alpha-1 blockers, atypical antipsychotics, tricyclic antidepressants, and, in women, brinzolamide and salbutamol. Medscape Medical News
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
GENEVA–(BUSINESS WIRE)–Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
Multivitamins Slow Biological Aging in a Large Trial
Dr JoAnn Manson discusses recent data on the use of multivitamin supplementation to slow aging, presented at the American Heart Association’s EPI/Lifestyle 2025 Scientific Sessions. Medscape Ob/Gyn